BR112022013730A2 - Métodos e composições para prevenir a adsorção de proteínas terapêuticas aos componentes do sistema de distribuição de drogas - Google Patents

Métodos e composições para prevenir a adsorção de proteínas terapêuticas aos componentes do sistema de distribuição de drogas

Info

Publication number
BR112022013730A2
BR112022013730A2 BR112022013730A BR112022013730A BR112022013730A2 BR 112022013730 A2 BR112022013730 A2 BR 112022013730A2 BR 112022013730 A BR112022013730 A BR 112022013730A BR 112022013730 A BR112022013730 A BR 112022013730A BR 112022013730 A2 BR112022013730 A2 BR 112022013730A2
Authority
BR
Brazil
Prior art keywords
drug delivery
delivery system
methods
compositions
system components
Prior art date
Application number
BR112022013730A
Other languages
English (en)
Inventor
Clapper Jonathan
Wee Siowfong
Li Gang
Original Assignee
Aptevo Res & Development Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptevo Res & Development Llc filed Critical Aptevo Res & Development Llc
Publication of BR112022013730A2 publication Critical patent/BR112022013730A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components

Abstract

MÉTODOS E COMPOSIÇÕES PARA PREVENIR A ADSORÇÃO DE PROTEÍNAS TERAPÊUTICAS AOS COMPONENTES DO SISTEMA DE DISTRIBUIÇÃO DE DROGAS. A divulgação fornece composições e métodos que reduzem a perda de proteína durante a distribuição da droga devido à adsorção da proteína em um ou mais componentes de um sistema de distribuição de droga. Em algumas modalidades, a divulgação fornece uma composição para prevenir a adsorção de proteínas a um ou mais componentes de um sistema de distribuição de drogas, a composição compreendendo succinato e polissorbato 80. Em algumas modalidades, a composição compreende ainda uma proteína terapêutica.
BR112022013730A 2020-01-13 2021-01-13 Métodos e composições para prevenir a adsorção de proteínas terapêuticas aos componentes do sistema de distribuição de drogas BR112022013730A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062960602P 2020-01-13 2020-01-13
PCT/US2021/013304 WO2021146336A1 (en) 2020-01-13 2021-01-13 Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components

Publications (1)

Publication Number Publication Date
BR112022013730A2 true BR112022013730A2 (pt) 2022-10-11

Family

ID=74798008

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022013730A BR112022013730A2 (pt) 2020-01-13 2021-01-13 Métodos e composições para prevenir a adsorção de proteínas terapêuticas aos componentes do sistema de distribuição de drogas

Country Status (11)

Country Link
US (1) US20230151102A1 (pt)
EP (1) EP4090368A1 (pt)
JP (1) JP2023512446A (pt)
KR (1) KR20220140500A (pt)
CN (1) CN115666639A (pt)
AU (1) AU2021207632A1 (pt)
BR (1) BR112022013730A2 (pt)
CA (1) CA3164420A1 (pt)
IL (1) IL294461A (pt)
MX (1) MX2022008655A (pt)
WO (1) WO2021146336A1 (pt)

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
BR0014486A (pt) * 1999-10-04 2002-09-17 Chiron Corp Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado
PT1441589E (pt) * 2001-11-08 2012-08-13 Abbott Biotherapeutics Corp Formulação farmacêutica líquida estável de anticorpos igg
ZA200506159B (en) * 2003-02-10 2006-10-25 Elan Pharm Inc Immunoglobulin formulation and method of preparation thereof
US7635472B2 (en) 2003-05-31 2009-12-22 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
WO2004106380A2 (en) 2003-05-31 2004-12-09 Micromet Ag Human-anti-human cd3 binding molecules
KR101229731B1 (ko) 2003-10-16 2013-03-07 암젠 리서치 (뮌헨) 게엠베하 다중특이적 탈면역화된 ｃｄ3-바인더
DE10348550A1 (de) * 2003-10-20 2005-06-16 Hexal Biotech Forschungsgmbh Stabile wässrige G-CSF-haltige Zusammensetzungen
EP2081553B1 (en) * 2006-10-06 2020-08-12 Amgen Inc. Stable antibody formulations
MX2009010611A (es) 2007-04-03 2010-03-26 Micromet Ag Enlazadores biespecificos, especificos para especies.
DK2644194T3 (en) * 2008-03-18 2017-07-03 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
DK2356153T3 (en) 2008-10-01 2016-07-04 Amgen Res (Munich) Gmbh Bispecific single CHAIN ​​PSMAXCD3 ANTIBODY THAT ARE SPECIFICALLY TO ALL SPECIES
NO2344540T3 (pt) * 2008-10-02 2018-04-28
SI2519543T1 (sl) 2009-12-29 2016-08-31 Emergent Product Development Seattle, Llc Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
US20130129723A1 (en) 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
CA2807127C (en) 2010-08-02 2019-02-12 Leslie S. Johnson Covalent diabodies and uses thereof
BR112013016153A2 (pt) * 2010-12-22 2017-07-11 Wyeth Llc composições imunogênicas estáveis de antígenos de staphylococcus aureus
SG195072A1 (en) 2011-05-21 2013-12-30 Macrogenics Inc Cd3-binding molecules capable of binding to human and non-human cd3
EP2839019A4 (en) 2012-04-20 2016-03-30 Emergent Product Dev Seattle CD3-BINDING POLYPEPTIDES
AU2015280480A1 (en) * 2014-06-26 2017-01-05 Amgen Inc. Protein formulations
WO2016094873A2 (en) 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
WO2016185016A1 (en) 2015-05-21 2016-11-24 Alligator Bioscience Ab Novel polypeptides
EP3352760A4 (en) * 2015-09-21 2019-03-06 Aptevo Research and Development LLC CD3 BINDING POLYPEPTIDES
BR112019005333A2 (pt) * 2016-09-21 2019-06-11 Aptevo Research And Development Llc proteínas de ligação a cd123 e composições e métodos relacionados
CN108261391B (zh) * 2016-12-30 2022-03-01 江苏太平洋美诺克生物药业有限公司 稳定的包含cd147单克隆抗体的药物制剂
JP2020530554A (ja) * 2017-07-20 2020-10-22 シートムエックス セラピューティクス，インコーポレイテッド 活性化抗体の特性を定性的および／または定量的に分析する方法およびその使用
EP3688033A4 (en) * 2017-09-29 2021-06-23 Janssen Biotech, Inc. NEW FORMULATIONS THAT STABILIZE LOW DOSE ANTIBODY COMPOSITIONS

Also Published As

Publication number Publication date
EP4090368A1 (en) 2022-11-23
WO2021146336A1 (en) 2021-07-22
IL294461A (en) 2022-09-01
JP2023512446A (ja) 2023-03-27
CA3164420A1 (en) 2021-07-22
US20230151102A1 (en) 2023-05-18
CN115666639A (zh) 2023-01-31
MX2022008655A (es) 2022-09-23
AU2021207632A1 (en) 2022-07-07
KR20220140500A (ko) 2022-10-18

Similar Documents

Publication Publication Date Title
van Zanten et al. Enteral glutamine supplementation in critically ill patients: a systematic review and meta-analysis
Yamasaki et al. Tranexamic acid reduces postoperative blood loss in cementless total hip arthroplasty
AR113422A2 (es) Agentes tensioactivos reconstituidos que tienen propiedades mejoradas
CL2011001406A1 (es) “formulación farmacéutica líquida estable que comprende un anticuerpo para il-1beta (acz885), manitol, tampón de histidina y polisorbato 80, con un ph entre 5,5-7,0”.
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
CL2019001366A1 (es) Formulaciones tamponadas exendina (9-39).
BR112018008805A8 (pt) proteínas de função dupla e composição farmacêutica que compreende a mesma
Spieth et al. Pharmacological therapies for acute respiratory distress syndrome
BRPI0317463B8 (pt) composto, composição farmacêutica compreendendo o mesmo e uso do referido composto no preparo de um medicamento para tratar uma doença amilóide de transtiretina
BRPI0520669A2 (pt) dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina
SV1999000149A (es) 1,2,3,4 - tetrahidroquinolinas - 2 - metil - 4 - carboxiamino ref. pc10024/82736/bb
UY31067A1 (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
BRPI0513100A (pt) métodos de tratamento da sìndrome de sjÍgren e artigos manufaturados
CY1107906T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει παραγωγα οιστετρολης για χρηση στην θεραπεια κατα του καρκινου
Assareh et al. Cannabidiol disrupts conditioned fear expression and cannabidiolic acid reduces trauma-induced anxiety-related behaviour in mice
FI964285A (fi) Taksaanien luokkaan kuuluviin johdannaisiin perustuvat farmaseuttiset valmisteet
CL2008002429A1 (es) Compuestos derivados de n-bencil, n'-arilcarbonilpiperazina, con actividad agonista de los receptores x del higado (lxrs); composicion farmaceutica que los contiene; y el uso de los compuestos en el tratamiento de la aterosclerosis.
WO2015023553A3 (en) Modulation of disease by administration of sulfur-containing, amino acid-specific small molecules
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
BR112022008497A2 (pt) Derivados terapêuticos da interleucina-22
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
BR112022013730A2 (pt) Métodos e composições para prevenir a adsorção de proteínas terapêuticas aos componentes do sistema de distribuição de drogas
BR0309825A (pt) Método e composição farmacêutica para reduzir a dor em um mamìfero que sofra de um neoplasma
BR112020004935A2 (pt) Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular
SG10201807034XA (en) A pharmaceutical composition for improving or preventing progression of Chronic Kidney Disease

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]